ROS1 and non-small cell lung carcinoma: Crizotinib has a beneficial effect on ROS-1 gene rearrangement, resulting in positive NSCLC due to its sequence similarity to the AKL and c-ros oncogene (ROS1) (Lim et al., 2017).